Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA site-wide banner about NIH’s terminology transition and related updates is no longer displayed.SummaryDifference1%

- Check19 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to show a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates about the change. It appears above the study record’s 403 error.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study record page now displays a 403 Forbidden message, preventing access to the trial details.SummaryDifference18%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.